Abstract Learning Objectives After completing this course, the reader will be able to: Define
characteristics of the interface between deep vein thrombosis and malignancy. Evaluate …

Objectives. Venous thromboembolism (VTE) occurs more frequently in cancer patients than
in non-cancer patients and outcomes are poor in patients with both cancer and thrombosis …

Background The use of warfarin sodium for treating venous thromboembolism in patients
with cancer is associated with a significant risk of recurrence and bleeding. The use of low …

Standard venous thromboembolic event (VTE) treatment practices including the use of
intravenous unfractionated heparin (UFH) for initial anticoagulation, oral warfarin for chronic …

The cancer patient who develops venous thromboembolism (VTE) faces a double jeopardy.
Changes in haemostasis leading to a prothrombotic state can be observed in over 90% of …

Venous thromboembolism (VTE) is a common complication of malignancy, and is
associated with significant morbidity and mortality. Anticoagulant therapy, in the form of …

BACKGROUND. Preclinical evidence suggests that anticoagulants, in particular the low‐
molecular‐weight heparins (LMWH), exert an antitumor effect, whereas clinical trials have …

An antineoplastic effect of anticoagulant agents has often been suggested. Heparin and
vitamin K antagonists have both been tested in this context. Heparin has been more …

There is increasing interest in the potential role of antithrombotic agents in the management
of cancer patients. Low molecular weight heparins (LMWHs) have generated particular …

Introduction The association of cancer and venous thromboembolism (VTE) becomes
increasingly important. VTE has been recognised as an increasingly frequent complication …